Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents
- 1 March 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (8) , 1040-1044
Abstract
Background— The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis examined whether these beneficial effects persist over the longer term. Methods and Results— This multicenter trial randomly assigned 238 patients to revascularization of single, de novo, native coronary artery lesions with sirolimus-eluting versus conventional bare-metal stents. Survival free from target lesion revascularization (TLR), target vessel failure (TVF), and MACE up to 3 years of follow-up was compared between the 2 treatment groups. Complete data sets were available in 94.2% of patients treated with sirolimus-eluting stents and in 94.1% of patients randomized to the control group. The cumulative 1-, 2-, and 3-year event-free survival rates were 99.2%, 96.5%, and 93.7% for TLR and 95.8%, 92.3%, and 87.9% for TVF, respectively, in the sirolimus-eluting stent group, versus 75.9%, 75.9%, and 75.0% for TLR and 71.2%, 69.4%, and 67.3% for TVF in the control group ( P P =0.002). One patient treated with a sirolimus-eluting stent died of a cardiac cause between 12 and 36 months. Conclusions— Treatment of de novo coronary stenosis with sirolimus-eluting stents was associated with a sustained clinical benefit and very low rates of TLR and of other MACE up to 3 years after device implantation.Keywords
This publication has 22 references indexed in Scilit:
- The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)JACC, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Sirolimus-Eluting Stent for the Treatment of In-Stent RestenosisCirculation, 2003
- Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent ImplantationCirculation, 2002
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Late acute thrombosis after paclitaxel eluting stent implantationHeart, 2001
- Late Coronary Occlusion After Intracoronary BrachytherapyCirculation, 1999
- Rapamycin inhibits vascular smooth muscle cell migration.Journal of Clinical Investigation, 1996
- TREATMENT WITH RAPAMYCIN AND MYCOPHENOLIC ACID REDUCES ARTERIAL INTIMAL THICKENING PRODUCED BY MECHANICAL INJURY AND ALLOWS ENDOTHELIAL REPLACEMENTTransplantation, 1995